Alireza Bahiraee

Alireza Bahiraee

Auto-generated profile, based on publicly available information

Alireza Bahiraee

Department of Medical Genetics, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
AAAmirsaeed S. Aghabozorgi
Amirsaeed S. Aghabozorgi
NANajmeh Ahangari
Najmeh Ahangari
TETasnim E. Eftekhaari
Tasnim E. Eftekhaari
PTParia N. Torbati
Paria N. Torbati
ABAlireza Bahiraee
Alireza Bahiraee
APAlireza Pasdar
Alireza Pasdar

25 April 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
ABAlireza Bahiraee
Alireza Bahiraee
REReyhane Ebrahimi
Reyhane Ebrahimi
RHRaheleh Halabian
Raheleh Halabian
AAAmirsaeed Sabeti Aghabozorgi
Amirsaeed Sabeti Aghabozorgi
JAJafar Amani
Jafar Amani

2 January 2020 in Critical Reviews in Clinical Laboratory Sciences
Verified
Journal Article
Closed access
SESolaleh Emamgholipour
Solaleh Emamgholipour
REReyhane Ebrahimi
Reyhane Ebrahimi
ABAlireza Bahiraee
Alireza Bahiraee
FNFarshad Niazpour
Farshad Niazpour
RMReza Meshkani
Reza Meshkani
Insulin resistance is associated with an increased risk of several metabolic disorders including type 2 diabetes, hypertension and cardiovascular diseases. Advances over the last decade have expanded our understanding of the molecular mechanisms underlying insulin resistance; however, many details of the mechanisms causing insulin resistance remain unknown. Recently, attention has shifted toward the role of epigenetics in insulin resistance. In this regard, acetylation of the histone tails has been widely investigated for its role in influencing both metabolic and mitogenic cascades of insulin signaling. More specifically, histone acetyltransferases and histone deacetylases, as major modulators of chromatin accessibility and gene expression, have been studied to determine a possible interconnectivity between the special effects of lysine acetylation status and tyrosine phosphorylation networks on the target proteins of downstream pathways involved in both metabolic and mitogenic cascades of insulin signaling. There is accumulating evidence for the post-translational modification effects of IGFR, InsR, IRS1/2, PI3K, Akt, GLUT4, FoxO, PGC-1α, PPAR, AMPK and MAPKs on insulin resistance and glucose homeostasis. In this paper, we review the importance of acetylation of these factors in the regulation of insulin signaling and glucose metabolism, with a primary focus on the target proteins of downstream signaling of insulin. We also provide an update on the interplay between epigenetic modification and the cellular genome in the context of insulin signaling and describe the possible effect of the environment on this epigenetic regulation.

1 December 2020 in Gene Reports
Verified
Journal Article
Closed access
ZAZohre Afshoon
Zohre Afshoon
ABAlireza Bahiraee
Alireza Bahiraee
FEFataneh Esmaeili
Fataneh Esmaeili
EMElaheh Mansouri
Elaheh Mansouri
MEMohammad Amin Emami
Mohammad Amin Emami
EEEbrahim Eftekhar
Ebrahim Eftekhar

1 September 2020 in Meta Gene
Verified
Journal Article
Closed access
ABAlireza Bahiraee
Alireza Bahiraee
ANAzim Nejatezadeh
Azim Nejatezadeh
HFHossein Farshidi
Hossein Farshidi
KMKeyanoosh Malekzadeh
Keyanoosh Malekzadeh
SESolaleh Emamgholipour
Solaleh Emamgholipour
MSMohammad Shekari
Mohammad Shekari

5 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CSCaspar Stephani
Caspar Stephani
DEDavid Ewers
David Ewers
DSDaniela Stausberg
Daniela Stausberg
DRDavid Rasche
David Rasche
ABAlireza Bahiraee
Alireza Bahiraee
MBMatthias Baehr
Matthias Baehr
Summary: Cerebrospinal fluid (CSF) biomarkers are generally assumed to reflect the severity and progression of neurodegenerative disease. We report three siblings carrying a novel heterozygous ATP13A2 variant (p.Pro629Ser) who challenge this paradigm. Despite only slowly progressive cognitive decline, axonal neuropathy, and leukodystrophy on MRI, all established CSF markers of neuronal destruction were profoundly abnormal, with tau and phosphorylated tau levels exceeding even those seen in Alzheimer’s disease or Creutzfeldt– Jakob disease. Patient fibroblasts revealed lysosomal alterations and abnormal amyloid precursor protein processing, and CSF polyamine levels were strongly reduced, consistent with impaired ATP13A2 function. These cases define a new ATP13A2-associated phenotype and, most importantly, demonstrate a striking dissociation between biomarker profiles and clinical course, questioning the general validity of CSF markers as direct indicators of disease severity.